Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment.
APDS
COVID19
IEI
SARS-CoV-2
activated PI3K delta syndrome (APDS)
long-lasting infection
monoclonal antibody
remdesivir
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
03
2022
accepted:
18
05
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the virus 105 days from the first positive swab and 7 days after monoclonal antibody administration. At genotyping, the SARS-CoV-2 virus resulted as wild type on all samples tested. This case shows the monoclonal antibodies' good tolerability and efficacy in reducing viral shedding in long-lasting infections refractory to other treatments.
Identifiants
pubmed: 35799775
doi: 10.3389/fimmu.2022.891274
pmc: PMC9253383
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Viral
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
891274Informations de copyright
Copyright © 2022 Rivalta, Amodio, Giancotta, Santilli, Pacillo, Zangari, Cotugno, Manno, Finocchi, Bernardi, Colagrossi, Gentile, Russo, Perno, Rossi, Cancrini and Palma.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leukemia. 2022 Apr;36(4):1025-1034
pubmed: 35105946
Am J Clin Exp Immunol. 2021 Oct 15;10(3):77-85
pubmed: 34824897
J Clin Immunol. 2021 Oct;41(7):1479-1489
pubmed: 34164762
J Allergy Clin Immunol. 2019 Jan;143(1):276-291.e6
pubmed: 29800648
N Engl J Med. 2022 Apr 14;386(15):1475-1477
pubmed: 35263535
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
J Allergy Clin Immunol. 2021 Sep;148(3):739-749
pubmed: 34087242
J Allergy Clin Immunol. 2016 Jul;138(1):210-218.e9
pubmed: 27221134
J Allergy Clin Immunol. 2021 Feb;147(2):520-531
pubmed: 32980424
Curr Opin Immunol. 2021 Oct;72:146-157
pubmed: 34052541
Blood. 2017 Nov 23;130(21):2307-2316
pubmed: 28972011
J Allergy Clin Immunol. 2019 Jul;144(1):236-253
pubmed: 30738173
J Clin Immunol. 2021 Oct;41(7):1463-1478
pubmed: 34114122
J Clin Immunol. 2021 Feb;41(2):345-355
pubmed: 33263173
Front Pediatr. 2021 Aug 27;9:703853
pubmed: 34540765
mSphere. 2021 Aug 25;6(4):e0048021
pubmed: 34431691
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2904-2906.e2
pubmed: 33894392
J Clin Med. 2021 Jul 24;10(15):
pubmed: 34362060
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
J Allergy Clin Immunol. 2021 Mar;147(3):870-875.e1
pubmed: 33338534
J Allergy Clin Immunol Pract. 2021 Oct;9(10):3575-3583
pubmed: 34182162
Influenza Other Respir Viruses. 2021 Jul;15(4):552-553
pubmed: 33715284
J Allergy Clin Immunol. 2022 Feb;149(2):557-561.e1
pubmed: 34780850
J Allergy Clin Immunol. 2020 Jul;146(1):58-60
pubmed: 32413374
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Front Immunol. 2021 Oct 04;12:727850
pubmed: 34671350
Allergy. 2022 Jan;77(1):282-295
pubmed: 34314546
J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4
pubmed: 27555459
Curr Opin Pediatr. 2021 Dec 1;33(6):648-656
pubmed: 34734915
Front Immunol. 2021 Jan 14;11:614086
pubmed: 33519822